G Michael Bixler1, George C Powers2, Reese H Clark3, M Whit Walker4, Veeral N Tolia5. 1. Division of Neonatology, Wright State University Boonshoft School of Medicine, Pediatrix Medical Group, Dayton, OH. 2. Division of Neonatology, Department of Pediatrics, Baylor College of Medicine, The Children's Hospital of San Antonio and Pediatrix Medical Group, San Antonio, TX. 3. The Pediatrix Center for Research, Education, and Quality, MEDNAX, Inc, Sunrise, FL. 4. Division of Neonatology, Greenville Health System, University of South Carolina School of Medicine - Greenville, Greenville, SC. 5. Division of Neonatology, Department of Pediatrics, Baylor University Medical Center and Pediatrix Medical Group, Dallas, TX. Electronic address: veeral.tolia@baylorhealth.edu.
Abstract
OBJECTIVE: To identify changes in the diagnosis, pharmacotherapy, and surgical ligation of patent ductus arteriosus (PDAs) in infants born premature and report on temporal changes in mortality and morbidity from a large volume of neonatal intensive care units (NICUs) in the US. STUDY DESIGN: We queried the Pediatrix Clinical Data Warehouse for all inborn infants without major anomalies born between 23 and 30 weeks' gestation from 2006 to 2015 for a diagnosis of PDA, use of indomethacin or ibuprofen, history of ductal ligation, mortality, and major morbidities. RESULTS: There were 829 091 infants entered in the Clinical Data Warehouse; 61 520 infants from 280 NICUs met our inclusion criteria. The diagnosis of PDA declined from 51% to 38% (P < .001), use of indomethacin or ibuprofen decreased from 32% to 18%, and PDA ligation decreased from 8.4% to 2.9% (both P < .001). During the study period, mortality decreased with no increase in any measured morbidity. Of the 163 sites with data for both periods, 128 (79%) showed a decrease in the diagnosis of PDA, and 132 (81%) showed a decrease in the use indomethacin and/or ibuprofen when 2011-2015 was compared with 2006-2010. Of 103 sites with at least 1 PDA ligation, 85 (83%) showed a decrease in PDA ligation in a similar comparison. CONCLUSIONS: In this large population of infants <30 weeks' gestation from 280 NICUs across the US, there were significant decreases in the diagnosis and treatment of the PDA. Although there was no evidence of increased morbidities, it remains uncertain how these changes may directly affect infant outcomes.
OBJECTIVE: To identify changes in the diagnosis, pharmacotherapy, and surgical ligation of patent ductus arteriosus (PDAs) in infants born premature and report on temporal changes in mortality and morbidity from a large volume of neonatal intensive care units (NICUs) in the US. STUDY DESIGN: We queried the Pediatrix Clinical Data Warehouse for all inborninfants without major anomalies born between 23 and 30 weeks' gestation from 2006 to 2015 for a diagnosis of PDA, use of indomethacin or ibuprofen, history of ductal ligation, mortality, and major morbidities. RESULTS: There were 829 091 infants entered in the Clinical Data Warehouse; 61 520 infants from 280 NICUs met our inclusion criteria. The diagnosis of PDA declined from 51% to 38% (P < .001), use of indomethacin or ibuprofen decreased from 32% to 18%, and PDA ligation decreased from 8.4% to 2.9% (both P < .001). During the study period, mortality decreased with no increase in any measured morbidity. Of the 163 sites with data for both periods, 128 (79%) showed a decrease in the diagnosis of PDA, and 132 (81%) showed a decrease in the use indomethacin and/or ibuprofen when 2011-2015 was compared with 2006-2010. Of 103 sites with at least 1 PDA ligation, 85 (83%) showed a decrease in PDA ligation in a similar comparison. CONCLUSIONS: In this large population of infants <30 weeks' gestation from 280 NICUs across the US, there were significant decreases in the diagnosis and treatment of the PDA. Although there was no evidence of increased morbidities, it remains uncertain how these changes may directly affect infant outcomes.
Authors: John M Dagle; Kelli K Ryckman; Cassandra N Spracklen; Allison M Momany; C Michael Cotten; Joshua Levy; Grier P Page; Edward F Bell; Waldemar A Carlo; Seetha Shankaran; Ronald N Goldberg; Richard A Ehrenkranz; Jon E Tyson; Barbara J Stoll; Jeffrey C Murray Journal: J Perinatol Date: 2018-12-05 Impact factor: 2.521
Authors: Sophia M Ansems; Haresh Kirpalani; Laura Mercer-Rosa; Yan Wang; Rachel K Hopper; María V Fraga; Erik A Jensen Journal: Neonatology Date: 2019-07-03 Impact factor: 4.035
Authors: Megan Barcroft; Christopher McKee; Darren P Berman; Rachel A Taylor; Brian K Rivera; Charles V Smith; Jonathan L Slaughter; Afif El-Khuffash; Carl H Backes Journal: Clin Perinatol Date: 2022-01-21 Impact factor: 3.430
Authors: Shannon E G Hamrick; Hannes Sallmon; Allison T Rose; Diego Porras; Elaine L Shelton; Jeff Reese; Georg Hansmann Journal: Pediatrics Date: 2020-11 Impact factor: 7.124
Authors: Wesley Jackson; Genevieve Taylor; David Selewski; P Brian Smith; Sue Tolleson-Rinehart; Matthew M Laughon Journal: Matern Health Neonatol Perinatol Date: 2018-11-19
Authors: Fernando R Moya; Jan Mazela; Paul M Shore; Steven G Simonson; Robert Segal; Phillip D Simmons; Timothy J Gregory; Carlos G Guardia; Judy R Varga; Neil N Finer Journal: BMC Pediatr Date: 2019-05-11 Impact factor: 2.125